Trials / Not Yet Recruiting
Not Yet RecruitingNCT07466901
A Single-arm, Multicenter, Phase II Clinical Study of Camrelizumab Combined With Famitinib in Adjuvant Therapy After Radical Resection of Cervical Cancer
- Status
- Not Yet Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Jin LI · Academic / Other
- Sex
- Female
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study is a single-arm, open-label, multicenter, exploratory clinical trial aimed at observing and evaluating the efficacy and safety of camrelizumab combined with famitinib in the adjuvant treatment of cervical cancer patients after surgery.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Camrelizumab | 200mg, intravenous drip for 0.5h, Q3W |
| DRUG | famotinib | 10mg, oral administration, QD |
Timeline
- Start date
- 2026-04-01
- Primary completion
- 2030-04-01
- Completion
- 2030-08-31
- First posted
- 2026-03-12
- Last updated
- 2026-03-12
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07466901. Inclusion in this directory is not an endorsement.